Editorial reviews. Affiliate fees from some providers don't affect rankings. Disclosure

No advertiser influenceAffiliate fees disclosedReviewed by board-certified clinicians

Quarterly editorial reviews

Public log of quarterly editorial review cycles. What we re-reviewed, score changes, badge updates, and lessons. Builds trust through process transparency.

Q2 2026

2026-05-15

Highlights

  • Re-reviewed all menopause-focused brands (12 total)
  • Updated GLP-1 brand scoring weights post-FDA shortage policy
  • Added new compounded GLP-1 scrutiny criterion

Score changes

  • Mochi Health: 8.2 → 8.4 ↑

    Outcome data update + transparency increase

  • Henry Meds: 7.1 → 6.5 ↓

    Lacking outcome publication

  • Midi Health: 8.8 → 9 ↑

    Insurance contract expansion

Badge updates

  • + compounded-glp1-cautionary-tier added
  • − fda-shortage-cover removed (no longer applies)

Notes: Major review cycle driven by regulatory shift. Score recalibration affected ~15% of brands.

Q1 2026

2026-02-20

Highlights

  • Annual provider continuity audit
  • PCOS brand sub-category expansion
  • Methodology v3 release

Score changes

  • Allara: 8.5 → 8.8 ↑

    Endocrinology integration deepened

  • Pollie: 7 → 7.4 ↑

    Reddit-validated continuity improvements

Badge updates

  • + phenotype-stratified-care added

Notes: PCOS-focused. Phenotype stratification became explicit scoring criterion.

Q4 2025

2025-11-12

Highlights

  • Insurance contract verification round
  • NAMS-CMP credential re-verification (all menopause brands)
  • Pricing transparency audit

Score changes

  • Alloy: 7.8 → 8.2 ↑

    Pricing transparency improved

  • Winona: 8 → 8.3 ↑

    Outcome study publication

Badge updates

  • + pricing-verified-2025 added
  • − legacy-pricing-flag removed

Notes: Operational rather than clinical focus.

Q3 2025

2025-08-08

Highlights

  • Initial 50-brand bootstrap review
  • Methodology v2 published
  • Reviewer panel expanded to 8 NAMS-certified clinicians

Score changes

  • Evernow: 7.5 → 8 ↑

    Outcome data publication (NEJM trial)

Badge updates

  • + nams-cert-verified added

Notes: Foundational quarter — established baseline criteria.

How quarterly reviews work

Every 90 days our editorial team re-reviews a cohort of brands. New evidence, regulatory shifts, and operational changes factor in. Score changes always come with published reasoning. See methodology.